NASDAQ: BYSI
Beyondspring Inc Stock

$1.70+0.02 (+1.19%)
Updated May 23, 2025
BYSI Price
$1.70
Fair Value Price
$0.06
Market Cap
$68.54M
52 Week Low
$0.98
52 Week High
$3.17
P/E
N/A
P/B
-2.42x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.76
Operating Cash Flow
N/A
Beta
0.86
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

BYSI Overview

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine BYSI's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
BYSI
Ranked
Unranked of 455

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$45.93A
$8.08A
$42.39A
View Top Biotech Stocks

Be the first to know about important BYSI news, forecast changes, insider trades & much more!

BYSI News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BYSI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BYSI ($1.70) is overvalued by 2,795.26% relative to our estimate of its Fair Value price of $0.06 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BYSI ($1.70) is not significantly undervalued (2,795.26%) relative to our estimate of its Fair Value price of $0.06 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BYSI's short-term assets ($31.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
There are 30 more BYSI due diligence checks available for Premium users.

Valuation

BYSI fair value

Fair Value of BYSI stock based on Discounted Cash Flow (DCF)

Price
$1.70
Fair Value
$0.06
Overvalued by
2,795.26%
BYSI ($1.70) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BYSI ($1.70) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation

BYSI price to earnings (PE)

For valuing profitable companies with steady earnings

Company
0x
Industry
-176.38x
Market
21.18x

BYSI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-2.42x
Industry
4.29x

BYSI's financial health

Profit margin

Revenue
$0.0
Net Income
-$2.1M
Profit Margin
0%

Assets to liabilities

Assets
$37.1M
Liabilities
$49.8M
Debt to equity
-1.76
BYSI's short-term assets ($31.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BYSI's long-term liabilities ($37.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BYSI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BYSI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$4.2M
Investing
$6.3M
Financing
$0.0

BYSI vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
BYSI$68.54M+1.19%N/A-2.42x
ARMP$68.41M+1.07%N/A-1.27x
SRZN$68.20M-2.15%-0.32x12.02x
ANL$68.20M+2.38%-1.14x2.68x
MNOV$69.16M+2.17%-6.13x1.39x

Beyondspring Stock FAQ

What is Beyondspring's quote symbol?

(NASDAQ: BYSI) Beyondspring trades on the NASDAQ under the ticker symbol BYSI. Beyondspring stock quotes can also be displayed as NASDAQ: BYSI.

If you're new to stock investing, here's how to buy Beyondspring stock.

What is the 52 week high and low for Beyondspring (NASDAQ: BYSI)?

(NASDAQ: BYSI) Beyondspring's 52-week high was $3.17, and its 52-week low was $0.98. It is currently -46.37% from its 52-week high and 73.47% from its 52-week low.

How much is Beyondspring stock worth today?

(NASDAQ: BYSI) Beyondspring currently has 40,316,320 outstanding shares. With Beyondspring stock trading at $1.70 per share, the total value of Beyondspring stock (market capitalization) is $68.54M.

Beyondspring stock was originally listed at a price of $16.80 in Mar 9, 2017. If you had invested in Beyondspring stock at $16.80, your return over the last 8 years would have been -89.88%, for an annualized return of -24.9% (not including any dividends or dividend reinvestments).

How much is Beyondspring's stock price per share?

(NASDAQ: BYSI) Beyondspring stock price per share is $1.70 today (as of May 23, 2025).

What is Beyondspring's Market Cap?

(NASDAQ: BYSI) Beyondspring's market cap is $68.54M, as of May 24, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Beyondspring's market cap is calculated by multiplying BYSI's current stock price of $1.70 by BYSI's total outstanding shares of 40,316,320.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.